That is a nice writeup, davidal66. I agree, especially about the timing of the interim analysis -- about July to Sept would be my guess; hoping the VB-111 arm pushes it out to later.
Regarding the CLDX trial, I think the main takeaway was what CLDX did in phase 2. In phase 2, they selected patients so that their outcomes would prove favorable for CLDX. In phase 3, they couldn't do that and the truth came out.
I don't think VBLT did that for VB-111.
News 
Market Data 
Discover 
